Shalby Limited SHALBY NSEPHARMA
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 15.6% over 5 years.
CONS
- Trading at a high P/E of 216.4.
- Earnings shrank at -51.4% CAGR over 5 years.
- Trading 36.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SHALBY Shalby Limited NSEPHARMA | 168.81 | 216.42 | ₹1,811.31 Cr | - | 7.29% | - | 15.64% | -51.38% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 275.63 Cr | 258.71 Cr | 296.43 Cr | 285.43 Cr | 272.13 Cr |
| Cost of Revenue | - | 153.22 Cr | 165.57 Cr | 178.86 Cr | 163.76 Cr | 160.25 Cr |
| Gross Profit | - | 122.42 Cr | 93.14 Cr | 117.56 Cr | 121.67 Cr | 111.88 Cr |
| Operating Expenses | - | 104.83 Cr | 77.43 Cr | 92.55 Cr | 97.43 Cr | 99.24 Cr |
| Operating Income | - | 17.59 Cr | 15.71 Cr | 25.02 Cr | 24.24 Cr | 12.64 Cr |
| EBITDA | - | 39.33 Cr | 22.72 Cr | 48.55 Cr | 46.09 Cr | 37.48 Cr |
| Interest Expense | - | 10.66 Cr | 7.23 Cr | 9.37 Cr | 9.64 Cr | 10.64 Cr |
| Pretax Income | - | 12.35 Cr | -73.80 L | 22.65 Cr | 19.07 Cr | 9.23 Cr |
| Tax Provision | - | 15.34 Cr | 11.45 Cr | 14.97 Cr | 11.80 Cr | 7.95 Cr |
| Net Income | - | -1.81 Cr | -11.02 Cr | 8.92 Cr | 8.38 Cr | 1.76 Cr |
| Diluted EPS | 0.22 | -0.28 | - | 0.71 | 0.68 | 0.12 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 698.95 Cr | 799.63 Cr | 928.22 Cr | 1,080.77 Cr |
| Cost of Revenue | 394.32 Cr | 435.11 Cr | 505.18 Cr | 634.97 Cr |
| Gross Profit | 304.63 Cr | 364.52 Cr | 423.04 Cr | 445.80 Cr |
| Operating Expenses | 222.01 Cr | 270.75 Cr | 294.70 Cr | 367.86 Cr |
| Operating Income | 82.62 Cr | 93.77 Cr | 128.34 Cr | 77.94 Cr |
| EBITDA | 127.90 Cr | 158.10 Cr | 194.83 Cr | 156.76 Cr |
| Interest Expense | 5.88 Cr | 7.97 Cr | 14.40 Cr | 35.27 Cr |
| Pretax Income | 79.15 Cr | 102.04 Cr | 128.19 Cr | 55.73 Cr |
| Tax Provision | 25.18 Cr | 34.37 Cr | 44.69 Cr | 53.81 Cr |
| Net Income | 54.12 Cr | 67.70 Cr | 84.08 Cr | 6.22 Cr |
| Diluted EPS | 5.00 | 6.30 | 7.83 | 0.58 |
Compounded Sales Growth
| 5 Years: | 15.64% |
| 1 Year: | -1.30% |
Compounded Profit Growth
| 5 Years: | -51.38% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -14.32% |
| 6 Months: | -19.98% |
| 3 Months: | +11.13% |
| 1 Month: | +5.07% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 1,193.54 Cr | 1,281.36 Cr | 1,607.53 Cr | 1,703.65 Cr |
| Current Assets | 448.87 Cr | 517.25 Cr | 552.25 Cr | 657.96 Cr |
| Cash & Equivalents | 55.55 Cr | 12.24 Cr | 27.18 Cr | 34.78 Cr |
| Inventory | 121.12 Cr | 185.40 Cr | 235.20 Cr | 319.21 Cr |
| Receivables | 100.99 Cr | 106.36 Cr | 144.63 Cr | 175.21 Cr |
| Total Liabilities | 317.35 Cr | 353.75 Cr | 599.75 Cr | 708.33 Cr |
| Current Liabilities | 172.46 Cr | 194.38 Cr | 323.27 Cr | 455.32 Cr |
| Long Term Debt | 87.39 Cr | 67.42 Cr | 175.97 Cr | 136.67 Cr |
| Total Debt | 174.07 Cr | 180.50 Cr | 377.87 Cr | 475.93 Cr |
| Total Equity | 876.32 Cr | 927.68 Cr | 1,000.37 Cr | 992.19 Cr |
| Shares Outstanding | 10.80 Cr | 10.80 Cr | 10.80 Cr | 10.80 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 18.92 Cr | 67.78 Cr | 19.60 Cr | -4.34 Cr |
| Investing Cash Flow | -60.30 Cr | -61.08 Cr | 38.07 Cr | -35.64 Cr |
| Financing Cash Flow | 90.46 Cr | -50.02 Cr | -150.69 Cr | 47.58 Cr |
| Capital Expenditure | -75.39 Cr | -18.48 Cr | -47.11 Cr | -71.45 Cr |
| Free Cash Flow | -56.48 Cr | 49.29 Cr | -27.51 Cr | -75.79 Cr |
| Net Change in Cash | 49.07 Cr | -43.33 Cr | -93.02 Cr | 7.60 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 43.6% | 45.6% | 45.6% | 41.2% |
| Operating Margin % | 11.8% | 11.7% | 13.8% | 7.2% |
| Net Margin % | 7.7% | 8.5% | 9.1% | 0.6% |
| ROE % | 6.2% | 7.3% | 8.4% | 0.6% |
| ROCE % | 8.1% | 8.6% | 10.0% | 6.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SHALBY